论文部分内容阅读
目的研究没食子酸抑制小鼠模型中人神经母细胞瘤增殖的作用以及对化疗药物的协同作用。方法建立人神经母细胞瘤SK-N-SH细胞株免疫活性C57BL/6j小鼠移植瘤模型,随机分配成4组,每组10只:①PBS荷瘤对照组,按PBS0.5ml/只,腹腔注射,作为阴性对照;②没食子酸组,按250mg/kg,1次/2d给药,连续2周;③环磷酰胺组,按75mg/kg给药,每周2次,连续2周,作为阳性对照;④没食子酸+环磷酰胺组,没食子酸在环磷酰胺给药前24h给药,没食子酸与环磷酰胺独立给药,剂量和时间同前。药物均9:00腹腔注射给药,每周监测相对肿瘤体积(RTV),治疗时间共2周,次日处死小鼠,称体质量和瘤质量(Wt)、计算抑瘤率(IR),BrdU标记检测移植瘤细胞增殖。结果没食子酸组、环磷酰胺组、没食子酸+环磷酰胺组在2周的移植瘤瘤质量分别为(4559.0±677.7)、(2117.0±749.6)、(637.7±319.6)mg,平均抑瘤率分别为36.94%、70.72%、91.18%,与PBS组比较差异有显著性(P<0.01),没食子酸+环磷酰胺组瘤质量与环磷酰胺组比较差异有显著性(P<0.01)。各给药组肿瘤增殖指数分别为0.1229±0.0219、0.1076±0.0156、0.0413±0.0130,与PBS组肿瘤增殖指数(0.2308±0.0759)比较差异有显著性(P<0.01),同时没食子酸+环磷酰胺组与没食子酸组或环磷酰胺组比较差异有显著性(P<0.01)。结论没食子酸具有抑制人神经母细胞移植瘤增殖、协同环磷酰胺抗肿瘤生长的作用。
Objective To study the effect of gallic acid on the proliferation of human neuroblastoma in mouse model and the synergistic effect of chemotherapeutics. Methods The transplanted tumor model of human neuroblastoma SK-N-SH cell line immunocompetent C57BL / 6j mice was established and randomly divided into 4 groups of 10 mice in each group: ① PBS control group, PBS0.5ml / Injection, as a negative control; ② gallic acid group, according to 250mg / kg, 1 / 2d administration for 2 weeks; ③ cyclophosphamide group, administered 75mg / kg twice a week for 2 weeks, as a Positive control; ④ gallic acid + cyclophosphamide group, gallic acid was given 24h before cyclophosphamide administration, and the dosage and time of gallic acid and cyclophosphamide were administered independently. The drugs were intraperitoneally injected at 9:00, and the relative tumor volume (RTV) was monitored weekly for a total of 2 weeks. The mice were sacrificed the next day, and the body mass and tumor mass (Wt) were calculated. BrdU labeling assay of tumor cell proliferation. Results The tumor mass of the group treated with gallic acid, cyclophosphamide and gallic acid + cyclophosphamide for two weeks were (4559.0 ± 677.7), (2117.0 ± 749.6) and (637.7 ± 319.6) mg, respectively (36.94%, 70.72%, 91.18%, respectively) compared with PBS group (P <0.01). There was significant difference between gallic acid + cyclophosphamide group and cyclophosphamide group (P <0.01). The proliferation index of tumor in each treatment group was 0.1229 ± 0.0219,0.1076 ± 0.0156,0.0413 ± 0.0130, which was significantly different from that in PBS group (0.2308 ± 0.0759) (P <0.01), meanwhile, gallic acid + cyclophosphamide There was a significant difference between the group and the gallic acid group or the cyclophosphamide group (P <0.01). Conclusion Gallic acid can inhibit the proliferation of xenografts in human neuroblastoma and synergize the anti-tumor effects of cyclophosphamide.